TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04134247

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 combined with chemotherapy
Description: PD-1 200 mg，d1; Rituximab 375mg/m2，d0（ the same as the chemotherapy group）~The chemotherapy chooses one of the following:~GDP：Gemcitabine 800-1000mg/m2, d1、8; Cisplatin 25mg/m2, d1-3; Dexamethasone 40mg, d1-4; GemOx：Gemcitabine 800-1000mg/m2, d1、8; Oxaliplatin 130mg/m2，d1; DA-EPOCH：Epirubicin 15mg／m２ ,d1-4; Etoposide 50mg／m２ ,d1-4; Vincristine 0.4mg/ ｍ２ ，d1-4; Cyclophosphamide 750mg/ ｍ２ , d５; Prednisone 60mg/m２/d, d1-5; ICE: Ifosfamide 1g/m２，d1-4; Cisplatin 25mg/m２, d1-4; Etoposide 60 mg／m２，d1-4; DICE: Ifosfamide 1 g／m２，dl-d4; Cisplatin 25mg/m２, d1-4; Etoposide 60 mg／m２，d1-4; Dexamethasone 10-20mg，d1-4; High dose MTX（Central recurrence）：MTX 3.5g／ｍ２,ｄ1; Hyper CVAD（B）：MTX 1g／ｍ２, d1; Cytarabine 2-3g／ｍ２, q12h, d2-3

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chemotherapy
Description: Rituximab 375mg/m2，d0（ Except for patients who relapsed within12 months after the last application of rituximab）~The chemotherapy chooses one of the following:~GDP：Gemcitabine 800-1000mg/m2, d1、8; Cisplatin 25mg/m2, d1-3; Dexamethasone 40mg, d1-4; GemOx：Gemcitabine 800-1000mg/m2, d1、8; Oxaliplatin 130mg/m2，d1; DA-EPOCH：Epirubicin 15mg／m２ ,d1-4; Etoposide 50mg／m２ ,d1-4; Vincristine 0.4mg/ ｍ２ ，d1-4; Cyclophosphamide 750mg/ ｍ２ , d５; Prednisone 60mg/m２/d, d1-5; ICE: Ifosfamide 1g/m２，d1-4; Cisplatin 25mg/m２, d1-4; Etoposide 60 mg／m２，d1-4; DICE: Ifosfamide 1 g／m２，dl-d4; Cisplatin 25mg/m２, d1-4; Etoposide 60 mg／m２，d1-4; Dexamethasone 10-20mg，d1-4; High dose MTX（Central recurrence）：MTX 3.5g／ｍ２,ｄ1; Hyper CVAD（B）：MTX 1g／ｍ２, d1; Cytarabine 2-3g／ｍ２, q12h, d2-3
Study: NCT01851720

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low dose fentanyl PCA

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard IV fentanyl bolus
Study: NCT00870363

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: maraviroc in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor)
Description: maraviroc 300mg 1 tablet taken twice a day without regard to food taken in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor) pre-determined with primary care physician

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: maraviroc plus raltegravir in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor)
Description: maraviroc 300mg 1 tablet taken twice a day without regard to food PLUS raltegravir 400mg 1 tablet taken twice a day without regard to food in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor) pre-determined with primary care physician

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: efavirenz [or other NNRTI (non-nucleoside reverse transcriptase inhibitor)]
Description: efavirenz 600mg 1 capsule is taken once a day without regard to food in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor) pre-determined with primary care physician
Study: NCT03646110

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Minimally invasive esophagectomy
Description: Minimally invasive esophagectomy is a surgical procedure for esophageal resection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minimally invasive esophagectomy
Description: Minimally invasive esophagectomy is a surgical procedure for esophageal resection
Study: NCT03974815

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACTIVE
Description: We will use 28.26cm\^2 round electrodes and a 2mA current for 30 minutes per day. This montage is known as bifrontal setup(F3-Anode, F4-Cathode) and has been previously used in major depression trials.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SHAM
Description: We will use 28.26cm\^2 round electrodes and a 0mA current for 30 minutes per day. This montage is known as bifrontal setup(F3-Anode, F4-Cathode) and has been previously used in major depression trials.
Study: NCT03674060

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYO-1644
Description: 100mg: SYO-1644 tablet, PO, 1 100mg tablet~150mg: SYO-1644 tablet, PO, 1 100mg tablet and 1 50mg tablet~200mg: SYO-1644 tablet, PO, 2 100mg tablet
Study: NCT04177849

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ACDF
Description: A 4-cm anterolateral transverse incision is made over the index level, on either the right or left side. Platysma is sectioned transversal to its fibers and the anterior aspect of the spinal column is bluntly exposed between the carotid sheath and the esophagus. The disk is excised, including the posterior longitudinal ligament. Disk fragments and/or osteophytes from the uncovertebral joint on the affected side are removed until the root is fully decompressed. Reconstruction is typically done with an interbody spacer, autologous bone graft and a stabilizing plate screwed to the adjacent vertebral bodies. A fusion cage with integrated screws may also be used according to the surgeon's preference.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PF
Description: A 4-cm longitudinal midline incision exposes the spinous processes of the adjacent vertebrae. The facet joint covering the index foramen is exposed through intermuscular planes. The root canal is opened as the medial third of the facet joint is removed with a high-speed diamond burr. The affected nerve root is decompressed by laterally undercutting the facet joint throughout its length.
Study: NCT04780906

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Wrist taping
Description: Wrist taping as used as standard in CrossFit practice
Study: NCT03674060

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYO-1644
Description: 100mg: SYO-1644 tablet, PO, 1 100mg tablet~150mg: SYO-1644 tablet, PO, 1 100mg tablet and 1 50mg tablet~200mg: SYO-1644 tablet, PO, 2 100mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYO-1644
Description: 100mg: SYO-1644 tablet, PO, 1 100mg tablet~150mg: SYO-1644 tablet, PO, 1 100mg tablet and 1 50mg tablet~200mg: SYO-1644 tablet, PO, 2 100mg tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nexavar tab
Description: Nexavar 200mg/tablet, PO, 1 tablet
Study: NCT01613781

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TOF count-guided partial NMB
Description: TOF count-guided partial NMB Using partial neuromuscular blockade to maintain train-of-four response of two, TOF response measured by the neuromuscular transmission module (NMT module)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: T1/Tc guided partial NMB
Description: Using partial neuromuscular blockade to maintain T1/Tc amplitude of 50%, T1/Tc amplitude measured by the neuromuscular transmission module (NMT)
Study: NCT01112527

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00299804
Description: Taken orally once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00299804
Description: Taken orally once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00299804
Description: Taken orally once a day
Study: NCT01515800

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text message reminder
Description: Receive text message
Study: NCT02636465

Intervention type: OTHER
Intervention: flight simulationin obese healthy adults or obese patients with or without COPD, OHS

Intervention type: OTHER
Intervention: flight simulationin obese healthy adults or obese patients with or without COPD, OHS

Intervention type: OTHER
Intervention: flight simulationin obese healthy adults or obese patients with or without COPD, OHS
Study: NCT01217060

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 20 mg/m2 given by vein (IV) over 1 hour once a week for up to 5 1/2 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 300 mg/m2 given by vein, continuously for 96 hours a week for about 5 1/2 weeks.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 50.4 Gy (1.8G/Fx/day) for about 5 1/2 weeks, Monday through Friday.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Esophagectomy
Description: Surgery to remove part of esophagus and nearby lymph nodes, approximately 8 to 10 weeks after completing chemoradiation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 10 mg IV 30 minutes prior to weekly Docetaxel.
Study: NCT01475630

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: physical therapy
Description: mobilisation of the jaw, exercises, boostering information on avoiding parafunctions

Intervention type: PROCEDURE
Group type: OTHER
Intervention: control
Description: relaxation
Study: NCT01959542

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PSA Blood Test
Description: Serum PSA will also be subsequently checked on the same day as each follow-up MR is performed, i.e. TP 1, 2 and 3, and right after finishing EBRT. 1-2 mls of blood will be sampled per blood test.
Study: NCT03050619

Intervention type: DRUG
Intervention: Empagliflozin

Intervention type: DRUG
Intervention: Other SGLT2 inhibitors

Intervention type: DRUG
Intervention: Other non-insulin GLDs
Description: metformin, sulfonylureas, DPP-4 inhibitors, GLP-1 agonists
Study: NCT02933242

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Ablative Body Radiotherapy
Description: The total dose and number of fractions will depend on the site of disease. Treatment will be given daily, or every other day, over 1 -3 weeks
Study: NCT04093778

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low dose high frequency training and Safe Delivery Phone Application
Description: The intervention period is a 9-month period where we will facilitate a quality improvement cycle using Low Dose High Frequency training with the Safe Delivery App as an anchor point and facilitate the integration into clinical practice through our Safe Delivery Focal Points at each hospital. All staff in maternity, paediatric wards and outpatient clinics will receive training and be encouraged to use the Safe Delivery App on a weekly basis.
Study: NCT04780906

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wrist taping
Description: Wrist taping as used as standard in CrossFit practice
Study: NCT04728269

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lactibiane Topic AD
Description: Application of Lactibiane topic AD twice a day (morning and evening) on one lesional area

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Application of placebo twice a day (morning and evening) on the symmetrical lesional area
Study: NCT02531412

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone
Description: After a major surgery event a time 0, 24h and 48h

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: After a major surgery event a time 0, 24h and 48h
Study: NCT04585048

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated Behavioral Therapy for Selective Mutism
Description: Cognitive Behavioral treatment including 24 weekly sessions
Study: NCT03933098

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Test Vaccine Vi-DT Typhoid conjugate
Description: * Manufacturer: SK Bioscience Co., Ltd.~* Ingredient: Purified Vi-polysaccharide conjugated to diphtheria toxoid~* Dose: 25 µg of Vi polysaccharide/0.5 mL, presented in 3 mL multi-dose glass vial

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Test Vaccine Vi-DT Typhoid conjugate
Description: * Manufacturer: SK Bioscience Co., Ltd.~* Ingredient: Purified Vi-polysaccharide conjugated to diphtheria toxoid~* Dose: 25 µg of Vi polysaccharide/0.5 mL, presented in 3 mL multi-dose glass vial
Study: NCT02732834

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: patients will fill out a questionnaire about their perceived stigma, satisfaction with communication, and psychological distress.

Intervention type: BEHAVIORAL
Intervention: Patient Interview
Description: Then they will participate in a brief in-person interview about their perceived stigma during the clinical consultation

Intervention type: BEHAVIORAL
Intervention: Audio recordings of clinical consultations
Study: NCT04492514

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mavrilimumab
Description: Treatment infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo infusion
Study: NCT02732834

Intervention type: BEHAVIORAL
Intervention: Audio recordings of clinical consultations

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Patients will fill out a questionnaire about their perceived stigma and satisfaction with their clinician's communication.
Study: NCT02843282

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Advanced Reasoning Training
Description: This is a strategy-based intervention to enhance frontal lobe function. Strategies equip participants to improve their strategic attention, integrated reasoning, and innovation abilities.
Study: NCT04008173

Intervention type: OTHER
Intervention: Non-interventional patient registry
Description: Non-interventional patient registry

Intervention type: OTHER
Intervention: Non-interventional patient registry
Description: Non-interventional patient registry

Intervention type: OTHER
Intervention: Non-interventional patient registry
Description: Non-interventional patient registry

Intervention type: OTHER
Intervention: Non-interventional patient registry
Description: Non-interventional patient registry

Intervention type: OTHER
Intervention: Non-interventional patient registry
Description: Non-interventional patient registry
Study: NCT00610922

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid (DHA)
Description: DHA 20 mg per day through 12 months of life
Study: NCT03234023

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: INTERVENTION GROUP
Description: Offer recommendations of healthy living habits and control of pharmacy administration
Study: NCT03270280

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nigella Sativa Oil
Description: The individuals will apply 55 drops of Nigella sativa Oil on gingivae twice daily for two weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: The individuals will apply 55 drops of Normal saline on gingivae twice daily for two weeks
Study: NCT00756379

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comprehensive therapy program for risk factor modification
Description: Patients enrolled in the comprehensive therapy arm will have a baseline myocardial perfusion PET and the support of a team of professionals aiming to modify and minimize all the known CAD risk factors. During the 5 year follow-up they will be educated and guided toward a healthy lifestyle by a dietician, an exercise physiologist/cardiovascular physician specialist.
Study: NCT04212026

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: The patients start treatment with nivolumab on day 1 after IRE and will be given nivolumab at a flat dose of 240 mg every 2 weeks (q2wk) for 5 cycles until Week 8.
Study: NCT03933098

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Test Vaccine Vi-DT Typhoid conjugate
Description: * Manufacturer: SK Bioscience Co., Ltd.~* Ingredient: Purified Vi-polysaccharide conjugated to diphtheria toxoid~* Dose: 25 µg of Vi polysaccharide/0.5 mL, presented in 3 mL multi-dose glass vial

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Vaccine Typbar TCV®
Description: * Manufacturer: Bharat Biotech~* Ingredient: Purified Vi capsular polysaccharide of Salmonella Ty2 conjugated to tetanus toxoid protein~* Dose: 0.5 ml
Study: NCT00411892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pioglitazone
Description: Tablets, 45 mg/day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pioglitazone
Description: Tablets, 45 mg/day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inhaled human insulin
Description: Treat-to-target dose titration scheme, inhalation.
Study: NCT03688191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Patients will receive oral sirolimus at a starting dose of 2 mg per day for 3 days and a sequential dose of 1mg per day, with dose adjusted according to tolerance and to maintain a therapeutic range of 6-15 ng/mL.
Study: NCT01024816

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Restorative yoga
Description: Group yoga sessions: Participants will attend 90 minute yoga group classes for 48 weeks: twice a week for 6 weeks, then once weekly during weeks 7 to 12, then every other week for weeks 13 - 24, and once a month for 6 months. We plan a progressive series of classes, with a subset of poses for each class and then selecting individual poses to focus on in each class.~Home yoga practice: Participants will be given a video disk (DVD) of the yoga postures at the start of the yoga intervention practice. We will also provide the yoga participants with a written manual with pictures and descriptions of each posture that they will be taught in the group sessions. The participants will be asked to practice the postures taught during their group sessions at home at least three times a week with the assistance of the DVD and manual. Each participant will be given a set of yoga props for their use at home. We will ask all participants to keep a log of their home practice sessions

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stretching
Description: Group classes: Participants will attend 90 minute group stretching classes for 48 weeks: twice a week for 6 weeks, then once weekly during weeks 7 to 12, then every other week for weeks 13 - 24, and once a month for 6 months. The stretches will address all body parts, including cervical, upper extremity, thoracic, lumbar, pelvic, and lower extremity musculature.~Home stretching practice: Each participant will receive a written manual with pictures and descriptions of each stretch that they will be learning in group sessions and a DVD with instruction on each of the stretches. The participants will be asked to practice the stretches taught during their group sessions at home at least three times a week with the assistance of the DVD and manual. Each participant will be given stretching supplies. We will ask all participants to keep a log of their home practice sessions.
Study: NCT02556801

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: SUBLIVAC FIX Phleum Prat.
Description: sublingual daily administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SUBLIVAC FIX Phleum Prat.
Description: sublingual daily administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SUBLIVAC FIX Phleum Prat.
Description: sublingual daily administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SUBLIVAC FIX Phleum Prat.
Description: sublingual daily administration
Study: NCT01109446

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma
Description: 27ml of autologous whole blood added to 3ml of ACD-A (Citrate Anticoagulant). After separation of the platelets, a high concentration of platelets (3-4ml Platelet Rich Plasma) is injected into the tendon through 7 perforations of the tendon, guided by ultrasound.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Isotonic Saline Solutions
Description: 3ml of Isotonic Saline Solution is injected into the tendon through 7 perforations of the tendon, guided by ultrasound.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolonacetonid
Description: Triamcinolonacetonid 40mg/ml. 40mg of Triamcinolonacetonid is mixed with 2ml of Lidocaine 10mg/ml. It is injected deep into the tendon, guided by ultrasound.
Study: NCT00390039

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV Placebo q3h PRN

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal morphine
Description: MNS075 15mg q3h PRN

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IN Placebo q3h PRN
Study: NCT00006773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV
Study: NCT04262076

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulpine with Polyamidoamine Dendrimer
Description: Removal of infected dentin in class I Cavities followed by application of Polyamidoamine Denrimer on caries affected Dentin that is washed out of the cavity after 30 secs then finally place Pulpine .

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pulpine with Polyamidoamine Dendrimer
Description: Removal of infected dentin in class I Cavities followed by application of Polyamidoamine Denrimer on caries affected Dentin that is washed out of the cavity after 30 secs then finally place Pulpine .
Study: NCT00448747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AEZS-130 (formerly ARD-07)
Description: A single oral administration of AEZS-130 as Growth Hormone Stimulation Test

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-ARG+GHRH
Description: A single administration of L-ARG+GHRH (iv bolus) followed by a 30min infusion of L-ARG as Growth Hormone Stimulation Test
Study: NCT04256681

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SNAP questionnaire
Description: The SNAP questionnaire will be administered 2 times in 2 consecutive days to evaluate its reliability. The questionnaire will be self-filled by the patient. Then the SPRS scale and, where possible, the 6MWT will be administered.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SNAP questionnaire
Description: The SNAP questionnaire will be administered 2 times in 2 consecutive days to evaluate its reliability. The questionnaire will be self-filled by the patient. Then the SPRS scale and, where possible, the 6MWT will be administered.
Study: NCT03421912

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cicaplast Balm B5
Description: The patients have to do 2 to 3 applications per day on the face, on lesions and in poultice in the evening in case of painful crack on the fingers

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dexeryl
Description: The patients have to do 2 to 3 applications per day on the face, on lesions and in poultice in the evening in case of painful crack on the fingers
Study: NCT02272712

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy
Description: psychoeducation about insomnia, relaxation training, sleep restriction, stimulus control, hypnotic tapering under direction of a physician, cognitive therapy, sleep hygiene